Adaptimmune Therapeutics PLC is committed to advancing the field of cellular immunotherapy. The company's corporate philosophy is centered around patient-centricity, innovation, and scientific excellence. Adaptimmune Therapeutics aims to provide novel treatments for cancer patients by harnessing the power of the immune system. By developing T-cell therapy products, such as its SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cells, Adaptimmune focuses on personalized medicine to deliver potentially life-changing outcomes. With a dedication to collaboration and research, Adaptimmune Therapeutics PLC strives to make significant advancements in the field of immuno-oncology to improve patient outcomes.

Adaptimmune Therapeutics PLC is primarily present in the United Kingdom and the United States.

Adaptimmune Therapeutics PLC has achieved significant milestones in its history. One major accomplishment is the development of its novel immunotherapies, which have shown promising results in treating various types of cancer. The company has also made advancements in expanding its product pipeline, forging strategic collaborations with renowned organizations, and achieving regulatory milestones. Adaptimmune Therapeutics PLC continues to conduct cutting-edge research and clinical trials, striving to revolutionize cancer treatment through its innovative cellular therapies. With its focus on advancing novel solutions, Adaptimmune Therapeutics PLC remains at the forefront of the fight against cancer.

Adaptimmune Therapeutics PLC is a leading biopharmaceutical company that specializes in developing novel immunotherapies for cancer treatment. Established in 2008, Adaptimmune has made significant strides in the field of T-cell therapy. The company's history is marked by groundbreaking research and collaborations with renowned institutions, including the University of Pennsylvania and GlaxoSmithKline. With a focus on utilizing T-cell receptors to target and destroy cancer cells, Adaptimmune aims to revolutionize cancer treatment and improve patient outcomes. Presently, Adaptimmune's innovative therapies are undergoing clinical trials, showcasing their dedication to providing hope for individuals battling cancer. As a pioneer in the field, Adaptimmune Therapeutics PLC continues to drive advancements in cancer immunotherapy.

The main competitors of Adaptimmune Therapeutics PLC in the market include companies such as Merck & Co., Inc., Novartis AG, Bristol-Myers Squibb Company, Amgen Inc., and Gilead Sciences, Inc.

Adaptimmune Therapeutics PLC is primarily active in the biotechnology and pharmaceutical industries.

Adaptimmune Therapeutics PLC operates under a cell therapy business model. The company focuses on developing and commercializing novel immunotherapies to treat various types of cancer. Through its unique T-cell receptor (TCR) platform, Adaptimmune aims to harness the power of the body's immune system to recognize and destroy cancer cells. By engineering and optimizing TCRs, the company enables T-cells to target cancer-specific proteins, known as antigens. This approach offers the potential for highly personalized treatments tailored to individual patients. Adaptimmune Therapeutics PLC seeks to revolutionize cancer treatment by providing innovative and effective immunotherapies that can potentially improve patient outcomes.

Adaptimmune Therapeutics hissesinin F/K oranı -1,21.

Adaptimmune Therapeutics KUV 17,38 dir.

Adaptimmune Therapeutics için AlleAktien Kalite Skoru 5/10'dur.

beklenen Adaptimmune Therapeutics cirosu 40,12 Milyon. USD dir.

beklenen Adaptimmune Therapeutics karı -577,34 Milyon. USD olarak gerçekleşmiştir.

Adaptimmune Therapeutics PLC is a biopharmaceutical company specializing in the development of cancer immunotherapies. It is headquartered in Oxfordshire, UK, and has branches in the USA. The company has a unique technology platform that allows it to target and destroy T cells specific to cancer cells. Adaptimmune primarily focuses on the open system of T-cell therapy and is developing a range of products to treat different types of cancer. Adaptimmune's business model is based on the research, development, and marketing of cancer immunotherapies. The company takes a broad research and development approach, encompassing its entire pipeline, with a focus on solid tumors as well as cancer types such as melanoma, hepatocellular carcinoma, and multiple myeloma. The company's main product currently is the drug JSMD194, a treatment approach for hepatocellular carcinoma. It is currently in phase II clinical trials, where it has shown promising effectiveness. Adaptimmune also has a strong partnership strategy to further develop and market its products. The company has partnerships with leading biotechnology and pharmaceutical companies such as GlaxoSmithKline, Merck & Co., and Genentech. An important part of Adaptimmune's business model is investment in research and development. The company has made significant investments in recent years to improve its technology platform and expand its product development pipeline. Adaptimmune also utilizes a unique leading end-to-end technology platform, providing it with a competitive advantage. The platform is designed to enable fast, optimized, and cost-effective operation. This ensures that the company can develop and bring products to market faster and more effectively than most competing companies. To further expand its business model, Adaptimmune plans to expand its product development pipeline and invest in new research areas. The company also plans to expand its partnerships and distribution channels to better market its products and increase revenue. Overall, Adaptimmune specializes in the development of cancer immunotherapies and has a strong research and development strategy that allows it to bring new products to market quickly. With a unique technology platform and a strong partnership strategy, Adaptimmune is well positioned to grow in the growing immunotherapy market.

Adaptimmune Therapeutics, yılda kez dağıtılmak üzere 0 USD tutarında temettü ödemektedir.

Adaptimmune Therapeutics için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Adaptimmune Therapeutics şirketinin ISIN kodu US00653A1079’dir.

Adaptimmune Therapeutics 'nin WKN'si A14SUX 'dir.

Adaptimmune Therapeutics için Ticker ADAP’dir.

Son 12 ay içerisinde Adaptimmune Therapeutics, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Adaptimmune Therapeutics, tahmini olarak 0 USD tutarında bir temettü ödemesi yapacak.

Adaptimmune Therapeutics şirketinin mevcut temettü verimi .

Adaptimmune Therapeutics dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

Adaptimmune Therapeutics, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 USD tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

Adaptimmune Therapeutics, 'Sağlık' sektörüne atanmıştır.

Son Adaptimmune Therapeutics tarihinde 0 USD tutarındaki en son temettüyü alabilmek için, hisseyi 16.02.2025 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 16.02.2025 olarak gerçekleşti.

2024 yılında Adaptimmune Therapeutics tarafından 0 USD olarak temettüler dağıtıldı.

Adaptimmune Therapeutics hisselerinin temettüleri USD olarak dağıtılır.